Amneal Pharmaceuticals (AMRX) Cash from Financing Activities (2017 - 2026)

Amneal Pharmaceuticals' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at -$59.1 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 50.78% year-over-year to -$59.1 million; the TTM figure through Mar 2026 stood at -$51.4 million (up 77.43% YoY), while the FY2025 annual figure was -$31.5 million, up 85.11% from the prior year.
• Cash from Financing Activities was -$59.1 million for Q1 2026 at Amneal Pharmaceuticals, down from -$10.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $59.4 million in Q3 2025 to a low of -$100.8 million in Q4 2023.
• Historically, Cash from Financing Activities has averaged -$36.6 million across 5 years, with a median of -$39.2 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities sank 354.87% in 2023, then surged 164.37% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at -$22.2 million in 2022, then sank by 354.87% to -$100.8 million in 2023, then surged by 39.3% to -$61.2 million in 2024, then surged by 83.47% to -$10.1 million in 2025, then plunged by 483.55% to -$59.1 million in 2026.
• The last three Cash from Financing Activities figures came in at -$59.1 million (Q1 2026), -$10.1 million (Q4 2025), and $59.4 million (Q3 2025), per Business Quant data.